Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.

Cancer research - 1 May 2007

Fernández Ariel, Sanguino Angela, Peng Zhenghong, Crespo Alejandro, Ozturk Eylem, Zhang Xi, Wang Shimei, Bornmann William, Lopez-Berestein Gabriel

Abstract excerpt

Protein kinases are central targets for drug-based cancer treatment. To avoid functional impairment, the cell develops mechanisms of drug resistance, primarily based on adaptive mutations. Redesigning a drug to target a drug-resistant mutant kinase constitutes a therapeutic challenge. We approach the problem by redesigning the anticancer drug imatinib guided by local changes in interfacial de-wetting propensities...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyrimidines
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Gastrointestinal Stromal Tumors

Share to Imatinib Mesylate

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 17483313
DOI: 10.1158/0008-5472.CAN-07-0345
PMCID: PMC2769247

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target.PMID 17483313Read ↗

Induced disorder in protein-ligand complexes as a drug-design strategy.Semantic proximity Read ↗

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read ↗

Revealing imatinib-kinase specificity via analyzing changes in protein dynamics and computing molecular binding affinitySemantic proximity Read ↗

Selectivity filters to edit out deleterious side effects in kinase inhibitors.Semantic proximity Read ↗

Lessons from Structural Biology for Understanding Drug Resistance in Gastrointestinal Stromal Tumors (GIST).Semantic proximity Read ↗

Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.Semantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

Molecular Dynamics-Guided Design and Chemoproteomic Profiling of Covalent Kinase Activity ProbesSemantic proximity Read ↗

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Semantic proximity Read ↗

Protein flexibility and dissociation pathway differentiation can explain onset of resistance mutations in kinasesSemantic proximity Read ↗

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and functionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.